xtensively drug-resistant tuberculosis (XDR-TB), which is TB resistant to isoniazid and rifampin plus one fluoroquinolone and a second-line injectable drug, represents an obstacle for the treatment and control of TB. Previously, we reported four XDR-TB cases and a high proportion of the Beijing genotype among multidrug-resistant TB (MDR-TB) isolates in the state of Valle del Cauca, Colombia (3), where a MDR-TB hot spot had been identified (7). According to the information of the local TB program, to date 21 XDR-TB cases have been diagnosed in the country, 14 of which were from this state.
TABLE 1
Phylogenetic and epidemiological data of XDR-TB isolates from Valle del Cauca, Colombia m a Spoligotypes are shown in octal format; lineages are designated according to the SITVIT2 database. b MIT numbers represent mycobacterial interspersed repetitive unit (MIRU) international types determined using 24 loci. The 8 unique profiles are defined as MIT101, -45, and -46 and five different orphan patterns. c Strains 03 and 04, which differ at a single MIRU locus (4 and 2 copies for MIRU-40, respectively), showed related spoligotype binary patterns SIT3010 and SIT881; hence, it is possible that SIT881 evolved by loss of a single block of spacers 25 to 31 either directly from SIT3010 or from a linked ancestor. d All the Beijing SIT190 strains (ID 06, 07, 08, 09, and 10) are highly related, since they represent a single locus variant in the 24-locus typing scheme (4, 3, 3, 3 bacterium tuberculosis isolates were determined using the SITVIT2 database (property of Institute Pasteur de la Guadeloupe).
In total, 10 XDR-TB patients were identified. Their median age was 30 years, and two cases (representing friends) were epidemiologically linked. All patients suffered from either bilateral disease or compromised lung function, and one underwent pneumonectomy. Three patients were labeled as primary resistant cases as they had no history of TB, suggesting active transmission of XDR-TB. The remaining patients had been intermittently exposed to second-line drugs. Six patients had a fatal outcome, one of them being HIV positive (Table 1) .
Shared types/lineages SIT190/Beijing, SIT62/H1, SIT881/unknown, SIT545/LAM2, and SIT3010/S were identified by spoligotyping. These genotypes, combined with the VNTR 24-locus results, yielded eight unique profiles, with MIRU-39 being the only locus that discriminated between the highly related Beijing/ SIT190 strains ( Table 1 ). The Beijing genotype was the most frequent (5/10), and one specific subtype, MIT45, was especially present among younger patients (Յ30 years old), new TB cases, and fatal outcomes (Table 1) .
Non-Beijing strains 03 and 04 differed only in a single locus (MIRU-40) and also revealed the highly related spoligopatterns SIT3010 and SIT881 (Table 1) . It is conceivable either that SIT881 evolved directly from SIT3010 or that they both derived from a common ancestor.
The distribution of the 5 XDR-TB shared types and lineages identified by spoligotyping in this state compared to the worldwide distribution revealed their high geographical specificity for South America and for Colombia in particular ( Table 2) .
The most frequent mutations associated with resistance to isoniazid and rifampin were S315T1 (80%) and S531L (70%) in the katG and rpoB genes, respectively. These mutations were previously shown to be related to MDR-TB transmission in Europe (2). A1401G (100%) and D94G (90%) were the most common mutations in the rrs and gyrA genes, associated with resistance to aminoglycoside-cyclic peptides and fluoroquinolone, respectively ( Table 1) .
Most of the XDR-TB patients had been treated with moxifloxacin, and all isolates had mutations in the gyrA gene; however, nine were phenotypically susceptible to this drug; suggesting alternative mutations or other resistance mechanisms. Moreover, one isolate (ID 03) did not exhibit concordance between the phenotypic and genotypic susceptibility profiles for isoniazid, emphasizing the importance of phenotypic drug susceptibility testing as the basis for treatment.
The presence of the same mutations in the Beijing isolates, in addition to the highly similar VNTR patterns, suggests the clonal expansion of this particular Beijing lineage. Haarlem SIT62/H1 was the second most frequent (2/10) sublineage, as in previous observations in Colombia (Table 2) (3). Multiple mutational events and clonal expansion of one or more hypervirulent and resistant strains (e.g., Beijing and Haarlem) may be occurring in Valle del Cauca (1, 4) .
The observed genetic relatedness between most of our XDR-TB isolates (Table 1) , as well as their high geographical specificity (Table 2) , highlights the emergence of XDR-TB strains within a pool of actively transmitted M. tuberculosis clinical isolates, which is highly alarming. Moreover, despite continuous efforts, a need remains to advance drug susceptibility testing and individualized treatment availability, especially since these patients have a prolonged infectious stage, resulting in a greater dissemination of these strains. We thank the personnel of the Secretary of Health from Buenaventura and Valle del Cauca, Hain Lifescience GmbH, and bioMérieux for their great contribution to this work. We also acknowledge the help of David 
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